<div id="readability-page-1">Investor Martin Shkreli’s big biotech short position is blowing up after the stock’s monumental rally over the past week, following a major clinical catalyst. Popularly known as “Pharma bro,” Shkreli initiated a short position against California-based Capricor Therapeutics Inc. ( CAPR ) two weeks ago, referring to the company’s HOPE-3 cell therapy for Duchenne Muscular Dystrophy as “COPE-3.” “It will not work. This is the company's only asset,” Shkreli said, yet the company cleared a major regulatory hurdle last week, with results showing “strong and definitive evidence that Deramiocel can meaningfully improve the course of Duchenne muscular dystrophy.” See Also: 10 Health Care Stocks With Whale Alerts In Today’s Session This led to a monumental rally in the stock, with its Momentum scores in Benzinga’s Edge Rankings following suit with a sharp spike over the course of the past week. <h2>Biotech Stock’s Momentum Score Spikes</h2> The Momentum score in Benzinga’s Edge Stock Rankings is assessed based on a stock’s price movements and volatility across multiple time frames, before being ranked as a percentile against all other stocks. A surge in a stock’s Momentum score is often indicative of a big uptick in volumes, volatility and the share price, often a result of a major news or fundamental catalyst. <h3>Capricor Therapeutics</h3> Following the positive results of its phase-3 HOPE-3 trial evaluating Deramiocel to treat Duchenne Muscular Dystrophy, the stock soared 440% within just one day, destroying Shkreli’s short position, which was expecting the stock to settle at around $2 per share. Shkreli has responded by criticizing the data, accusing the company’s CEO, Linda Marban, of lying and giving the results a positive spin. The stock’s momentum score has nonetheness witnessed a steep surge, rising from 3.83 to 96.4 within the span of a week, following its strong rally. Besides this, the stock has a favorable price trend in the short, medium and long terms. Click here for deeper insights into the company, its products and operations. &lt;figure class=&#34;wp-block-image aligncenter size-full&#34;&gt;<img width="728" height="110" src="https://imageproxy.pbkrs.com/https://editorial-assets.benzinga.com/wp-content/uploads/2025/12/08041502/Screenshot-2025-12-08-at-2.44.23-PM.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://editorial-assets.benzinga.com/wp-content/uploads/2025/12/08041502/Screenshot-2025-12-08-at-2.44.23-PM.png"/>&lt;/figure&gt; Read More: <ul> <li>Best Biotech Penny Stocks</li> </ul> Photo courtesy: Shutterstock</div>

Capricor治療

馬丁·什克雷利對 Capricor Therapeutics Inc.的空頭頭寸正在失敗，因為該股票在 HOPE-3 細胞療法的積極三期試驗結果公佈後飆升了 440%。該股票的動量得分從 3.83 飆升至 96.4，表明波動性和股價的增加。什克雷利批評這些數據，指責首席執行官歪曲結果。該股票在短期、中期和長期內的有利價格趨勢持續

馬丁·施克雷利的生物科技空頭頭寸正在遭受巨大損失，因為股票飆升了 440%：動量得分急劇上升